about
Clinical Outcomes of Patients with HIV Undergoing Lead Extraction for Infectious and Noninfectious Indications.Anti-α4 Integrin Antibody Blocks Monocyte/Macrophage Traffic to the Heart and Decreases Cardiac Pathology in a SIV Infection Model of AIDS.Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes.Direct Targeting of Macrophages With Methylglyoxal-Bis-Guanylhydrazone Decreases SIV-Associated Cardiovascular Inflammation and Pathology.Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting.Screening and risk assessment for coronary artery disease in HIV infection: an unmet need.Cardiovascular Disease in the Setting of Human Immunodeficiency Virus Infection.
P2860
Q35826419-14F68AF5-27DF-4A6F-A6B0-43AB1A1975BAQ36168754-940F5945-6314-42A1-8C65-77CB2A0A7A62Q38936060-16201AAB-54DB-4A9C-92CE-ADF48EA61B9BQ38988925-70FC37BB-DE23-4117-8172-6DA883D8CDC4Q40144330-4A16A602-D536-41FD-AB0E-CA41124BFE07Q40565869-7046494D-2EAA-47D9-90FC-E3FE6D20A72DQ51779710-EF2B90DD-4FD8-4166-9D08-5595390F4F59
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cardiovascular disease in human immunodeficiency virus.
@en
type
label
Cardiovascular disease in human immunodeficiency virus.
@en
prefLabel
Cardiovascular disease in human immunodeficiency virus.
@en
P2860
P356
P1476
Cardiovascular disease in human immunodeficiency virus.
@en
P2093
P2860
P304
P356
10.1111/IMJ.12381
P577
2014-04-01T00:00:00Z